SHANAFELT ARMEN B.,GREVE JEFFREY M.,JESMOK GARY,LEMBACH KENNETH J.,WETZEL GAYLE D.
申请号：
SK17242000
公开号：
SK288100B6
申请日:
1999.05.13
申请国别(地区):
SK
年份:
2013
代理人:
摘要：
t is described a human interleukin (IL-2) mutein, which preferentially activates T lymphocytes over Natural Killer cells, a pharmaceutical composition containing thereof combined with a pharmaceutical carrier, a polynucleotide comprising a DNA sequence encoding said mutein and degenerated variants thereof, a vector containing that polynucleotide, a prokaryotic host cells transformed with such vector and use of mutein for manufacture of a medicament for treating of mammal suffering from disorder curable by IL-2.t is described a human interleukin (IL-2) mutein, which preferentially activates T lymphocytes over Natural Killer cells, a pharmaceutical composition containing thereof combined with a pharmaceutical carrier, a polynucleotide comprising a DNA sequence encoding said mutein and degenerated variants thereof, a vector containing that polynucleotide, a prokaryotic host cells transformed with such vector and use of mutein for manufacture of a medicament for treating of mammal suffering from disorder curable by IL-2.
